US rejects AZ and FibroGen’s anaemia drug roxadustat by Lucy Parsons | Aug 12, 2021 | News | 0 FDA has requested an additional clinical trial on the safety of roxadustat Read More
AZ’ roxadustat successful in late-stage trial by Anna Smith | Jul 25, 2019 | News | 0 The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27. Read More
AZ confirms cardiovascular safety with roxadustat results by Anna Smith | May 16, 2019 | News | 0 The companies will begin discussions with the US Food and Drug Administration (FDA) to prepare for regulatory submission. Read More
Astellas’ kidney disease drug shows promise in PhIII by Selina McKee | Sep 20, 2018 | News | 0 A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints. Read More